£810 / $1295 / €985
Slovenia's healthcare system is relatively developed and effective, particularly compared with other markets in Central and Eastern Europe. The country's health system faces short-term challenges as a result of austerity budgets which will limit public spending on healthcare andaredesigned to reduce the number of services covered under compulsory health insurance. Long-term threats concern the availability of public funds in a tightening economic and fiscal environment and projected rises in age-related health expenditure.
Headline Expenditure Projections
Pharmaceuticals : EUR762mn (US$1.06mn) in 2011 to EUR769mn (US$977mn) in 2012; +1.0% in local currency terms and -7.8% in US dollar terms.
Healthcare: EUR3.40bn (US$4.73bn) in 2011 to EUR3.42bn (US$4.34bn) in 2012; 0.5% in local currency terms and -8.2% in US dollar terms.
Medical Devices: EUR235mn (US$327mn) in 2011 to EUR239mn (US$304mn) in 2012; +1.5% in local currency terms and -7.3% in US dollar terms.
Risk/Reward Rating: In our Q1 13 assessment, we have revised downward our Pharmaceuticals and HealthcareRisk/Reward Ratings (RRRs)forCentral and Eastern Europe (CEE), mainly due to the attractiveness of Poland, Greece and the Czech Republic getting worse.Downward revisions to our industry rewards indicators for CEE are a result of moderated outlooks for 2013 in many pharmaceutical markets, as well unfavourable revisions to our currency assumptions, affecting our assessment of market growth when measured in US dollars. Slovenia's Risk/Reward Rating (RRR) score remains weak - a combination of economic factors and the acknowledgement that the government may retain its focus on cost savings have resulted in a slightly less optimistic outlook for 2013 and 2014.
The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.
Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of Espicom's industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.